Want to see CLYM full AI Analyst Report?
CLYM Stock Chart & Stats
$12.84
-$0.05(-0.39%)
At close: 4:00 PM EDT
$12.84
-$0.05(-0.39%)
Day’s Range― - ―
52-Week Range$1.54 - $18.14
Previous Close$12.82
Volume1.21M
Average Volume (3M)1.35M
Market Cap
$992.50M
Enterprise Value$811.24
Total Cash (Recent Filing)$183.12M
Total Debt (Recent Filing)$1.31M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding57,436,256
10 Day Avg. Volume1,017,170
30 Day Avg. Volume1,347,738
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$23.00Price Target Upside79.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Capitalization And Minimal LeverageVery low leverage and a materially larger equity base reduce refinancing pressure and provide funding flexibility. This balance-sheet strength can support continued clinical development through multiple catalysts, although future losses may require additional capital.
Phase 2 Renal Disease Trial Has BegunProgressing into a mid-stage renal disease trial validates execution of the development plan and expands the company’s clinical footprint through its China collaboration. Phase 2 data could provide a more meaningful read on efficacy and commercial potential.
Encouraging Budoprutug Clinical ProfileEarly activity in heavily pretreated immune thrombocytopenia patients, including those previously treated with rituximab, supports continued development in an area of unmet need. Favorable tolerability and durable responses may strengthen the candidate’s competitive positioning.
Bears Say
No Revenue And Persistent Operating LossesThe company has no commercial revenue to offset development expenses, leaving results dependent on funding and clinical execution. Persistent losses limit visibility into eventual profitability and increase sensitivity to trial outcomes, timelines, and capital availability.
Sustained Negative Cash GenerationOngoing cash consumption reflects the substantial cost of advancing a clinical pipeline without product revenue. Continued negative free cash flow will reduce financial flexibility over time and may require repeated financing before the business can fund itself.
Material Future Equity Dilution RiskThe financing facility improves access to capital, but issuing stock to fund recurring losses can dilute existing holders. The expanded equity program and inclusion of prefunded warrants also create a persistent share-supply overhang while commercialization remains distant.
Climb Bio News
CLYM FAQ
What was Climb Bio, Inc.’s price range in the past 12 months?
Climb Bio, Inc. lowest stock price was $1.54 and its highest was $18.14 in the past 12 months.
What is Climb Bio, Inc.’s market cap?
Climb Bio, Inc.’s market cap is $992.50M.
When is Climb Bio, Inc.’s upcoming earnings report date?
Climb Bio, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were Climb Bio, Inc.’s earnings last quarter?
Climb Bio, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.209 by $0.029.
Is Climb Bio, Inc. overvalued?
According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued.
Does Climb Bio, Inc. pay dividends?
Climb Bio, Inc. does not currently pay dividends.
What is Climb Bio, Inc.’s EPS estimate?
Climb Bio, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Climb Bio, Inc. have?
Climb Bio, Inc. has 57,436,256 shares outstanding.
What happened to Climb Bio, Inc.’s price movement after its last earnings report?
Climb Bio, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.209. Following the earnings report the stock price went up 12.269%.
Which hedge fund is a major shareholder of Climb Bio, Inc.?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (79.13% Upside)
$23.00 (79.13% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
767.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.02%
Trailing 12-Months
Company Description
Climb Bio, Inc.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$23.00
▲(79.13% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
20.10% Insiders
5.54% Mutual Funds
54.37% Other Institutional Investors
11.88% Public Companies and
Individual Investors